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Abstract
The immunosuppressive agent cyclosporin A (CsA), a calcineurin inhibitor which blocks T cell
activation has provided the pharmacologic foundation for organ transplantation. CsA exerts
additional effects on non-immune cell populations and may adversely effect microvascular
endothelial cells, contributing to chronic rejection, a long-term clinical complication and significant
cause of mortality in solid-organ transplants, including patients with small bowel allografts. Growth
of new blood vessels, or angiogenesis, is a critical homeostatic mechanism in organs and tissues,
and regulates vascular populations in response to physiologic requirements. We hypothesized that
CsA would inhibit the angiogenic capacity of human gut microvessels. Primary cultures of human
intestinal microvascular endothelial cells (HIMEC) were used to evaluate CsA's effect on four in
vitro measures of angiogenesis, including endothelial stress fiber assembly, migration, proliferation
and tube formation, in response to the endothelial growth factor VEGF. We characterized the
effect of CsA on intracellular signaling mechanisms following VEGF stimulation. CsA affected all
VEGF induced angiogenic events assessed in HIMEC. CsA differentially inhibited signaling pathways
which mediated distinct steps of the angiogenic process. CsA blocked VEGF induced nuclear
translocation of the transcription factor NFAT, activation of p44/42 MAPK, and partially inhibited
JNK and p38 MAPK. CsA differentially affected signaling cascades in a dose dependent fashion and
completely blocked expression of COX-2, which was integrally linked to HIMEC angiogenesis.
These data suggest that CsA inhibits the ability of microvascular endothelial cells to undergo
angiogenesis, impairing vascular homeostatic mechanisms and contributing to the vasculopathy
associated with chronic rejection.
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Background
The calcineurin inhibitor cyclosporin A (CsA) is a potent
immunosuppressive agent that has formed the pharmaco-
logic cornerstone of solid organ transplantation. CsA pre-
vents the activation of lymphokine genes essential for T
cell proliferation by disrupting calcium-dependent signal
transduction pathways in leukocytes [1]. Although phar-
macologic studies of CsA have focused primarily on T cell
responses, there is emerging evidence that this agent may
exert potent effects on blood vessels, promoting arterial
hypertension, inducing long-term vascular dysfunction,
and contributing to obliterative vasculopathy in chronic
transplant rejection [2-5]. At the present time, chronic
rejection with its associated vasculopathy, is the major
cause of late allograft dysfunction, including patients with
intestinal transplants [6,7].
In solid-organ transplantation, the vascular endothelium
has received attention because of its unique role as the
interface between the donor graft and the host's circulat-
ing immune cells, and as a focus of acute rejection [8,9].
More recent investigation has demonstrated that the
endothelium plays a central role in chronic rejection,
where inappropriate activation of endothelial cells results
in obliterative vasculopathy and accelerated post-trans-
plant atherosclerosis [10], a major cause of morbidity and
mortality in solid organ transplant recipients. Activation
of graft endothelium in chronic rejection may result from
host/graft immunologic attack, as well as dysfunction
associated with transplant immunosuppression [5]. In
transplantation of the small bowel, microvascular dys-
function may contribute to more significant problems
with both acute and chronic rejection in these patients.
Indeed, small bowel transplantation has been one of the
more problematic clinical areas in the realm of solid
organ grafts, where patients require increased immuno-
suppressive regimens and have had overall, less successful
clinical outcomes [11-13].
The growth of new microvessels, or angiogenesis, is now
appreciated to be a critical biologic process involved in tis-
sue homeostasis. Angiogenesis is initiated by local activa-
tion of genes encoding diffusable angiogenic factors, or by
the release of vascular growth factors which subsequently
act on local microvasular cell populations, as well as by a
decrease in local angiostatic factors, including interferon
beta [14]. Angiogenesis involves an orchestrated sequence
of steps which include endothelial activation, stress fiber
assembly, fibrinolysis, proteolytic degradation of the
basement membrane and the extracellular matrix, migra-
tion, proliferation and neovascularization [15]. One of
the major angiogenic growth factors is the vascular
endothelial growth factor (VEGF), which selectively
induces activation, migration, proliferation and tube for-
mation in endothelial cells in vitro. VEGF is a 34–42 kDa
glycoprotein which exerts its biological effects on
endothelial cells through its two major tyrosine kinase
receptors, VEGFR1/Flt-1 (fetal liver kinase-1) and
VEGFR2/Flk-1/KDR (kinase insert domain containing
receptor). By binding to these receptors, VEGF activates
various signaling cascades, including the mitogen acti-
vated protein kinase family (ERK1/2, p38 MAPK and
SAPK/JNK) and phosphoinositol3-kinase (PI3 kinase)
[16,17]. A downstream result of these signaling events is
the expression of COX-2, which plays an integral role in
VEGF induced angiogenesis [18-20]. Finally, investigation
has demonstrated a pivotal role for the transcription fac-
tor nuclear factor activated in T-cells (NFAT) in the ang-
iogenic signaling of VEGF in human umbilical vein
endothelial cells (HUVEC) [21], which is inhibited by
CsA. Thus, there is a potential role for CsA in blocking
angiogenesis in microvascular cell populations, poten-
tially through its effect on NFAT.
An integrated analysis of the effect of CsA on the multiple
stages of the angiogenic process in human organ specific
microvascular endothelial cells has not been performed to
date. Studies evaluating the effect of CsA on human
umbilical vein endothelial cells [22] may not accurately
reflect microvascular events, and are further complicated
by their wide functional variability in tissue culture, caus-
ing discrepant results reported by different laboratories
[23]. In addition, it is also now appreciated that human
microvascular endothelial cells derived from differenti-
ated, organ specific vascular beds have been shown to dif-
fer significantly from HUVEC in their responsiveness to
cytokines, the expression profile of antigens, and the elab-
oration of secretory products [24-27]. We investigated the
mechanisms of VEGF-induced endothelial cell signaling
and angiogenesis in HIMEC, an organ specific microvas-
cular cell population, and the effect of CsA on four in vitro
components of angiogenesis, including stress fiber assem-
bly, migration, proliferation/growth and tube formation.
Results
VEGF, but not TNF-α/LPS, enhances growth of HIMEC
We have previously shown that VEGF is a potent stimulus
for in vitro growth and proliferation of HIMEC [28,29].
Additional studies have demonstrated that in vitro activa-
tion of HIMEC with TNF-α/LPS will result in inflamma-
tory activation, expression of cell adhesion molecules and
increased leukocyte binding which is mediated by activa-
tion of NF-κB and mitogen activated protein kinases [30].
Because MAPK activation has been linked to proliferation
of various cell types, including endothelial cells, we per-
formed in vitro growth studies to assess the effect of VEGF
and TNF-α/LPS on HIMEC. HIMEC monolayers stimu-
lated with VEGF for 24 hr resulted in a significant increase
in cell number, while TNF-α/LPS had essentially no effect
and was similar to unstimulated cell growth (Figure 1). AsCell Communication and Signaling 2004, 2 http://www.biosignaling.com/content/2/1/3
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expected, VEGF stimulation of HIMEC resulted in activa-
tion of all three members of MAPK family members (p44/
42 MAPK, JNK, p38 MAPK; Figure 2), which was similar
to that achieved by stimulation with TNF-α/LPS [30]. This
data demonstrates that MAPK activation is a common
pathway involved in both the inflammatory and ang-
iogenic activation of HIMEC, but also suggested that
growth and proliferation would involve additional intrac-
ellular signaling mechanisms.
Effect of CsA on VEGF induced stress fiber assembly in 
HIMEC
CsA exerts potent inhibitory effects on TNF-α/LPS
induced activation of HIMEC, by inhibiting p38 MAPK
activation [30]. We began experiments investigating the
effect of CsA on VEGF induced angiogenic activation in
HIMEC by assessing endothelial stress fiber assembly and
cytoskeletal architectural rearrangement, an early step in
angiogenesis. HIMEC rapidly demonstrated stress fiber
assembly following 1–10 ng/ml VEGF stimulation (Figure
3). However, higher dosages of VEGF (i.e. 50 ng/ml)
resulted in a reduction in stress fiber assembly, suggesting
that the effects of this growth factor follow a bimodal dis-
tribution, where higher concentrations result in dimin-
ished biologic effects. CsA decreased actin stress fiber
formation following VEGF which was similar to the effect
of the p38 MAPK inhibitor SB203580. The p44/42 MAPK
inhibitor PD098059 failed to affect VEGF induced stress
fiber assembly. VEGF (10 ng/ml) induced stress fiber
assembly in HIMEC was abolished by receptor blockade
using neutralizing monoclonal antibodies, suggesting
that this phenomenon was mediated through VEGFR2.
Immunosuppressive agents inhibit VEGF induced 
migration, proliferation and growth of HIMEC
Angiogenesis involves multiple events in endothelial
cells, including migration and proliferation. HIMEC
migration demonstrated a bimodal distribution in
response to increasing dosages of VEGF, where 1–10 ng/
ml resulted in a higher response compared to 50 ng/ml
(Figure 4 left panel). CsA significantly inhibited VEGF
induced migration of HIMEC, which was similar to the
p38 MAPK inhibitor SB203580 (Figure 4 right panel).
FK506, an additional calcineurin inhibitor and potent
immunosuppressive agent, exhibited a similar effect com-
pared to CsA, which exhibited a low level increase in base-
line migration, which was similar to that observed in
VEGF stimulated cells. Rapamycin, an immunosuppres-
sive agent which functions through a distinct mechanism,
interacting with m-TOR (mammalian target of
VEGF, but not TNF-α/LPS stimulation of HIMEC results in  enhanced cell growth Figure 1
VEGF, but not TNF-α/LPS stimulation of HIMEC results in 
enhanced cell growth. HIMEC monolayers stimlulated with 
VEGF (50 ng/ml) for 24 hr resulted in a significant increase in 
cell number, while TNF-α/LPS had essentially no effect and 
was similar to unstimulated cell growth.
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VEGF enhances phosphorylation of MAPK family members of  signaling proteins in HIMEC Figure 2
VEGF enhances phosphorylation of MAPK family members of 
signaling proteins in HIMEC. Activation of p44/42 MAPK, 
JNK and p38 MAPK in HIMEC by VEGF was assessed using 
Western blot analysis. Total cell lysates from cultured 
HIMEC stimulated with VEGF (10–50 ng/ml), were subjected 
to SDS-PAGE and immunoblotted with phospho-specific 
anti-ERK 1/2, JNK and p38 MAPK antibodies. VEGF enhances 
phosphorylation of all three MAPK members, as compared 
with total ERK. The time of induction ranged from 1 to 120 
min as detailed in the materials and methods section. Maxi-
mum detection of p42/44 MAPK was seen at 30 min (shown); 
Maximum activation of p38 MAPK was detected at 10 min in 
response to VEGF; JNK maximum activation was seen at 5 
min following VEGF activation. Coomassie staining of the 
polyacrylamide gel confirms equal amounts of total protein 
loaded. The representative figure shown is from one of three 
independent experiments.
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rapamycin), demonstrated a stimulatory effect on resting
cells and a diminished inhibition of VEGF induced
HIMEC migration compared to CsA and FK506. Taken
together with the previous experiments, these data suggest
that CsA is a potent inhibitor of both stress fiber forma-
tion and cell migration, which is potentially mediated
through effects on p38 MAPK activation.
Cell cycle re-entry and DNA replication in endothelial
cells is a requisite step in angiogenesis. Experiments were
performed on HIMEC proliferation assessing 3H
thymidine uptake in response to low (10 ng/ml) and high
(50 ng/ml) dose VEGF. Proliferation in response to VEGF
(10 ng/ml) revealed a complete inhibition of increased
thymidine uptake in HIMEC treated with CsA and the
COX-2 inhibitor NS398 (Figure 5 right panel). In contrast
to previous studies in stress fiber assembly and migration,
Stress fiber assembly in HIMEC following VEGF stimulation Figure 3
Stress fiber assembly in HIMEC following VEGF stimulation. VEGF (10 ng/ml) induced stress fiber assembly was attenuated by 
anti-VEGFR2, CsA and SB203580 but not PD098059. The effect of VEGF on stress fiber polymerization in HIMEC was assessed 
by fluorescence staining with fluorescein phalloidin, a substance which specifically detects F-actin. Confluent HIMEC monolay-
ers were grown on fibronectin-coated glass chamber slides, and stimulated with VEGF (1–10 ng/ml, 15 min) prior to staining. 
Control, minimal stress fibers are demonstrated in unstimulated HIMEC (negative control). VEGF, at 10 ng/ml but not at 50 
ng/ml strongly increased stress fiber assembly. At some intercellular junctions, a marked retraction of endothelial cells is nota-
ble, leading to scattered interruptions in continuity of the endothelial cell monolayer. Pre-incubation of HIMEC with SB203580 
(p38 MAPK inhibitor, 5 µM), CsA (0.1 µM) and neutralizing anti-VEGFR2 antibody (10 µg/ml, 15 min, 37°C) markedly attenu-
ated stress fiber assembly by VEGF (note diminished fluorescence intensity and less pronounced stress fiber induction). Fluo-
rescence microscopic images were obtained with an original magnification of 400×, at a fixed shutter speed. Figure shows 
representative images from one of three independent experiments.
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the p44/42 MAPK inhibitor PD098059 was more effective
than the p38 MAPK inhibitor SB203580 in blocking thy-
midine uptake in HIMEC stimulated with 10 ng/ml VEGF.
At high dosages of VEGF (i.e. 50 ng/ml), CsA continued to
block proliferation, which was partially inhibited by
SB203580 and PD098059 (Figure 5 left panel).
Experiments evaluating endothelial growth in a wounded
monolayer, with cell expansion across a leading edge,
again demonstrated a potent angiogenic effect of VEGF
compared to cells which were unstimulated (Figure 6).
CsA treated HIMEC monolayers were completely
unresponsive to VEGF, and grew at rates similar to
untreated cells. In these experiments, the most potent
inhibitor of monolayer expansion was the p44/42 MAPK
inhibitor PD098059, while SB203580 failed to block this
phenomenon.
Matrigel™ In vitro-Tube Formation in HIMEC
In vitro-angiogenesis of HIMEC was assessed by tube for-
mation assays. HIMEC seeded onto Matrigel™ in complete
growth medium display formation of robust tube-like
structures within 8 hr (data not shown), with further mat-
uration after 16 hr (Fig 7 upper panel). CsA (0.1 µM),
PD098059 (10 µM) and NS398 (10 µM) exhibited a
marked inhibitory effect on the formation of tube-like
structures by HIMEC, visible by the disruption of these
capillary-like microvessels and cells remaining coherent
VEGF at low concentration (1–10 ng/ml) is a potent chemoattractant for HIMEC migration in vitro Figure 4
VEGF at low concentration (1–10 ng/ml) is a potent chemoattractant for HIMEC migration in vitro. Effect of VEGF on HIMEC 
migration assessed by a Transwell chemotaxis assay. HIMEC migrating across fibronectin-coated polycarbonate filters (pore 
size, 8 µm) were quantified using modified Wright's stain (Diff-Quik) and bright field microscopy. Left panel; VEGF (1–10 ng/ml) 
elicits strong chemotactic properties in HIMEC. Note the biphasic dose response, as higher concentrations of VEGF (50 ng/ml 
and higher) do not result in marked chemotaxis in HIMEC. Right panel; VEGF (10 ng/ml) induced chemotaxis in HIMEC is 
decreased by specific inhibitors of p38 MAPK (SB203580), CsA and FK506 but not Rapamycin. As shown in the right panel, 
VEGF acts as a potent chemoattractant for HIMEC. This chemotactic response was potently diminished by SB203580 (5 µM), 
CsA (0.1 µM) and FK506 (50 nM). * = p < 0.05 versus positive control; n.s. = not significant. No VEGF, denotes the negative 
control while VEGF (10 ng/ml) served as the positive control. All conditions were assessed in triplicate, and data are expressed 
as mean number of migrated cells per high-power field (200×) ± S.E.
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in spherical clusters (Fig 7 lower panel). These findings
indicate that activation of p44/42 MAPK and COX-2 is
required for endogenous in vitro-tube formation in
HIMEC.
VEGF enhances phosphorylation of MAPK
The ability of VEGF to induce MAPK phosphorylation was
assessed by immunoblot analysis using phospho-specific
antibodies. VEGF stimulation of HIMEC leads to a
marked phosphorylation and activation of extracellular
signal regulated kinase (ERK 1/2, p44/42 MAPK), SAPK/
JNK and p38 MAPK. ERK 1/2 phosphorylation by VEGF in
HIMEC was time and dose dependent, reaching its maxi-
mum at 30 min of stimulation by 50 ng/ml of VEGF (Fig-
ure 8). PD098059 and CsA abolished p44/42 MAPK
phoshorylation in HIMEC whereas SB203580 did not.
Equal loading of protein was assured by western blotting
after stripping and reprobing membranes with non-phos-
VEGF enhances the proliferation rate of HIMEC in vitro Figure 5
VEGF enhances the proliferation rate of HIMEC in vitro. VEGF-induced HIMEC proliferation was assessed by 3H thymidine 
uptake. 4 × 104 HIMEC/well were stimulated for 12 hr with increasing concentrations of VEGF (0, 1, 10, and 100 ng/ml) and 
pulsed for 6 hr with 1 µCi/ml 3H thymidine. 3H thymidine uptake in total cell lysates was measured in a β-counter. left; VEGF 
enhanced HIMEC proliferation at 50 ng/ml while low concentrations (i.e. 10 ng/ml VEGF) did not. right; The inhibitory effects 
of PD098059, CsA and NS398 but not SB203580 on VEGF (50 ng/ml) induced proliferation response in HIMEC. HIMEC pre-
incubation with PD098059, CsA and NS398 significantly inhibited VEGF induced proliferation response in HIMEC. All condi-
tions were assessed in triplicate, and data are expressed as percent of control 3H thymidine uptake (0 ng/ml VEGF) ± S.E. *, p 
< 0.05 versus control.
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pho-specific-MAPK antibodies along with Coomassie
staining of the polyacrylamide gel after separation of pro-
teins. Phosphorylation of p38 MAPK by VEGF in HIMEC
was maximal at 5 min, and SB203580, a specific inhibitor
of p38 MAPK resulted in inhibition of the p38 MAPK
activity but not its phosphorylation. CsA partially inhib-
ited p38 MAPK activation in HIMEC in response to VEGF
(Figure 9). Control experiments were performed which
demonstrated no effect of SB203580, PD098059 on the
non-VEGF stimulated HIMEC (data not shown).
Effect of VEGF on Nuclear Factor of Activated T cells 
(NFAT) in HIMEC
VEGF stimulation of HIMEC leads to dephosphorylation
of NFATp and its nuclear translocation from the cytosol as
detected by western blot analysis using specific anti-NFAT
antibodies. Stimulation of HIMEC with 50 ng/ml VEGF
resulted in a complete NFATp translocation to the nucleus
within 15 min which was sustained for 2 hr. Nuclear
NFATp declined to undetectable levels after 5 hr (Figure
10). Pre-treatment of HIMEC with 0.1 µM of CsA pre-
vented NFATp translocation to the nucleus in VEGF stim-
ulated cells, as shown by western blot analysis of nuclear
extracts (Figure 11). Proinflammatory activation of
HIMEC using a combination of TNF-α/LPS did not result
in a nuclear translocation of NFATp, demonstrating the
specificity of this signaling pathway in angiogenesis.
DNA-binding activity of NFATp, NF-κB and AP-1 in VEGF 
activated HIMEC
Having shown that VEGF activates NFATp in HIMEC, we
next determined the binding of the transcription factor to
an NFAT site of the human COX-2 promoter (nucleotides
-117 to -91), NF-κB (nucleotides -277 to-211 containing
the NFκB site of the human COX-2 promoter) and AP-1
(nucleotides -82 to -58 containing the NFAT-AP1 site of
the human COX-2 promoter) [22]. Figure 12 shows the
electrophoretic mobility shift assay analysis of the nuclear
extracts from VEGF activated HIMEC which demonstrate
a marked increase in NFAT sequences of the COX-2 pro-
HIMEC growth across a leading edge demonstrated that VEGF (10 ng/ml) (■ ) resulted in increased monolayer expansion com- pared to cells which were unstimluated (◆ ) Figure 6
HIMEC growth across a leading edge demonstrated that VEGF (10 ng/ml) (■ ) resulted in increased monolayer expansion com-
pared to cells which were unstimluated (◆ ). CsA (0.1 µM) treated monolayers completely blocked the effect of VEGF, and 
grew at rates similar to untreated cells (● ). The most potent inhibitor of monolayer expansion was the p44/42 MAPK inhibitor 
PD098059 (▲ ), whereas p38 MAPK inhibitor SB203580 had no effect on HIMEC monolayer expansion ().
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moter bound to nuclear proteins of VEGF activated but
not TNF-α/LPS stimulated HIMEC. The NFAT DNA-bind-
ing activity in HIMEC was inhibited by 0.1 µM of CsA pre-
treatment (Figure 12 left panel). Next we studied the effect
of VEGF on NF-κB activation in HIMEC. Figure 12
(middle panel) demonstrates that VEGF fails to activate
NF-κB in HIMEC. This was in contrast to TNF-α/LPS
activation of HIMEC which resulted in marked NF-κB
activation. CsA had no effect on TNF-α/LPS induced bind-
ing of NF-κB (Figure 12 middle panel). VEGF stimulation
of HIMEC also resulted in increased AP-1 activity, as
shown in Figure 12 (right panel), AP-1 probe efficiently
and specifically bound to nuclear proteins and this bind-
ing was not sensitive to CsA pre-treatment
To visualize the nuclear translocation of NFAT, the p65
subunit of NF-κB and the AP-1 components c-fos and c-
Jun, we performed immunofluorescence staining of VEGF
stimulated HIMEC using specific antibodies (i.e. anti-
NFATp, p65, c-fos and c-Jun). As shown in Figure 13, in
unstimulated HIMEC, NFATp was detected in the cyto-
plasm and following VEGF activation was translocated to
the nucleus, whereas TNF-α/LPS activation did not result
in nuclear translocation of NFAT. CsA pre-treatment
resulted in abrogation of the NFATp nuclear translocation
(Figure 13). Thus, the immunofluorescence results con-
firmed the data obtained from western blot analysis.
Interestingly, VEGF did not lead to translocation of the
NF-κB-subunit p65, whereas TNF-α/LPS activation of
In vitro tube formation of HIMEC requires activation of ERK 1/2 (p44/42 MAPK) Figure 7
In vitro tube formation of HIMEC requires activation of ERK 1/2 (p44/42 MAPK). In vitro endothelial tube formation assays 
employed Matrigel™ as a three-dimensional extracellular matrix. HIMEC in complete growth medium (5 × 104) were seeded 
onto 24-well plates containing Matrigel™ (5 mg/ml). Where indicated, the medium was supplemented with CsA (0.1 µM), p38 
MAPK inhibitor SB203580 (5 µM), specific inhibitors of MAPK kinase (PD098059, 10 µM), and COX-2 inhibitor NS398 (10 
µM), respectively. Cells receiving DMSO served as a vehicle control, and were equivalent to no treatment (data not shown). 
Naive HIMEC seeded in complete growth medium display robust tube formation. Addition of VEGF to growth medium 
resulted in enhanced tube formation. All three inhibitors markedly abrogated spontaneous tube formation of HIMEC seeded in 
complete growth medium. Note the cells remaining adherent in spherical clusters, lacking mature tube-like structures.Cell Communication and Signaling 2004, 2 http://www.biosignaling.com/content/2/1/3
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VEGF enhanced phosphorylation of ERK 1/2 (p44/42 MAPK) and p38 MAPK in HIMEC is diminished by specific inhibitors of  ERK 1/2, p38 MAPK and CsA Figure 8
VEGF enhanced phosphorylation of ERK 1/2 (p44/42 MAPK) and p38 MAPK in HIMEC is diminished by specific inhibitors of 
ERK 1/2, p38 MAPK and CsA. Activation of ERK 1/2, a member of the MAPK superfamily, in HIMEC by VEGF was assessed 
using Western blot analysis. Total cell lysates from VEGF stimulated HIMEC with or without inhibitors were subjected to SDS-
PAGE and immunoblotted with phosphorylated and non-phosphorylated specific anti-ERK 1/2 antibodies. VEGF enhanced 
phosphorylation of ERK 1/2 was diminished by CsA and PD098059, as compared with total ERK 1/2. TNF-α/LPS stimulation of 
HIMEC served as a positive control for ERK 1/2 activation.
Activation of p38 MAPK, a member of the MAPK superfamily, in HIMEC by VEGF was assessed using Western blot analysis, as  described above using phosphorylated and non-phosphorylated specific anti-p38 MAPK antibodies Figure 9
Activation of p38 MAPK, a member of the MAPK superfamily, in HIMEC by VEGF was assessed using Western blot analysis, as 
described above using phosphorylated and non-phosphorylated specific anti-p38 MAPK antibodies. VEGF enhanced phosphor-
ylation of p38 MAPK is diminished by CsA and decreased by SB203580 (inhibits the p38 MAPK activity but not its phosphoryla-
tion), as compared with total p38 MAPK. Again, TNF-α/LPS activation served as a positive control. Coomassie blue staining of 
the polyacrylamide gel confirms equal amounts of total protein loaded. The representative figure shown is from one of three 
independent experiments.
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HIMEC resulted in p65 translocation from cytosol to the
nucleus and was unaffected by CsA (Figure 14). VEGF
stimulation of HIMEC also resulted in nuclear transloca-
tion of c-fos and c-Jun, which was also not affected by CsA
(Figure 15).
VEGF increases COX-2 gene expression in HIMEC
Activation of HIMEC with VEGF also resulted in enhanced
COX-2 expression at the mRNA level as detected by RT-
PCR using COX-2 specific primers. Enhanced COX-2
expression was time dependent, increased from 3–6 hr
which was maximal, declining from 12 to 24 hr. Pre-treat-
ment of HIMEC with 0.1 µM of CsA, 10 µM NS398 and 10
µM PD098059 completely abolished VEGF induction of
COX-2, whereas SB203580 did not exert an inhibitory
effect on expression of this gene product (Figure 16).
There was no detectable change in the level of COX-1
mRNA after VEGF stimulation. β-actin gene expression
was used as an internal control in these experiments.
The effect of various cytokines on COX-2 protein expres-
sion was determined. As demonstrated in Figure 17 both
TNF-α/LPS and VEGF were strong activators of COX-2
expression in HIMEC. Enhanced COX-2 protein expres-
sion in HIMEC following VEGF activation was time
dependent, which increased at 3 hr and declined after 24
hr, as detected by western blotting using a specific anti-
COX-2 antibody. In marked contrast, levels of COX-1
protein expression remained unchanged following VEGF
stimulation of HIMEC (Figure 18). Consistent with the
Effect of VEGF on Nuclear Factor of Activated Tcells (NFAT) activation in HIMEC Figure 10
Effect of VEGF on Nuclear Factor of Activated Tcells (NFAT) activation in HIMEC. VEGF stimulation of HIMEC leads to 
dephosphorylation of NFATp and its nuclear translocation from the cytosol as detected by western blot analysis using specific 
anti-NFAT antibodies. Stimulation of HIMEC with 50 ng/ml VEGF resulted in a complete NFATp translocation to the nucleus 
within 15 min which was sustained for 2 hr. Nuclear NFATp declined to undetectable levels after 5 hr.
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gene expression data, pre-treatment of HIMEC with 0.1
µM of CsA completely abolished VEGF induction of COX-
2 protein expression (Figure 18).
Discussion
In this study, we demonstrate that CsA exerts potent
effects on the angiogenic capacity of human microvascu-
lar endothelial cells, differentially inhibiting multiple
stages in the in vitro angiogenic process. This inhibitory
effect of CsA on VEGF function in HIMEC involved 1)
actin assembly and stress fiber formation, 2) cell migra-
tion, 3) proliferation and monolayer expansion (growth),
and 4) tube formation. Furthermore, experiments focus-
ing on the effect of CsA on signaling events following
VEGF induced HIMEC activation demonstrated blockade
of the DNA binding activity of the transcription factor
NFAT, complete inhibition of p44/42 MAPK activation,
partial inhibition of p38 MAPK, and complete inhibition
of COX-2, with no effect on AP-1 activation. Furthermore,
our data demonstrate that these signaling cascades play
specific roles in the four components of angiogenesis
which were modeled in our human organ specific micro-
vascular system, and were differentially affected by CsA.
Thus, CsA effects multiple signaling pathways in VEGF
induced angiogenesis, which may ultimately impact on
vessel growth, an important component of vascular
homeostasis and may contribute to the vasculopathy of
chronic rejection.
Receptor tyrosine kinases and their ligands play a crucial
role in vascular development, and considerable progress
has been made toward understanding the cellular and
molecular events in angiogenesis [31]. Activation of
endothelial signal transduction pathways are essential
aspects of neovascularization, as endothelial activation
must occur for cells to undergo angiogenesis. Although
the biological functions of VEGF and its role in the ang-
iogenic process have been extensively explored, the intra-
cellular signaling pathways that lead to distinct gene
expression patterns and altered endothelial physiology in
response to VEGF in human organ specific microvascular
endothelial cell populations remain incompletely
defined, nor has the VEGF induced signaling in
endothelial cells been characterized in an integrated fash-
ion. Data obtained in this study demonstrate that VEGF
activation of HIMEC results in activation all three MAPK
members (ERK1/2, p38 MAPK and SAPK/JNK) and
resulted in increased both migration and proliferation.
Signaling through MAPKs are heavily dependent on the
immediate environment which surrounds the endothelial
cell. ERK1/2 is generally involved with cell growth and
proliferation, whereas SAPKs are usually known to
transduce stress signals [32]. Here we have shown that
biological effects of VEGF on endothelial cells are concen-
tration dependent, as 10 ng/ml VEGF resulted in HIMEC
migration, p38 MAPK activation and actin/stress fiber for-
mation while higher concentrations (i.e. 50 ng/ml)
resulted in activation of p44/42 MAPK, COX-2 expres-
sion, NFAT activation and increased cell proliferation.
This is in agreement with Rousseau et al. [33] and
Seetharam et al. [34], who have shown that exposure of
human umbilical vein endothelial cells (HUVEC) to con-
centrations of VEGF that increase cell migration also pro-
motes actin polymerization, formation of stress fibers and
Pre-treatment of HIMEC with 0.1 µM of CsA prevented NFATp translocation to the nucleus in VEGF stimulated cells, as  shown by Western blot analysis of nuclear extracts Figure 11
Pre-treatment of HIMEC with 0.1 µM of CsA prevented NFATp translocation to the nucleus in VEGF stimulated cells, as 
shown by Western blot analysis of nuclear extracts. Proinflammatory activation of HIMEC using combination TNF-α/LPS did 
not result in a nuclear translocation of NFATp.
NFATp
VEGF - - +          +        +         +            - -
CsA - - - - +         +             - -
TNF-α/LPS - - - - - - +         +
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recruitment of vinculin to ventral plaques. Actin fibers dis-
appeared in HIMEC exposed to higher concentrations of
VEGF (50–100 ng/ml) and cell migration was also dimin-
ished. SB203580, a p38 MAPK specific inhibitor blocked
both cell migration and actin polymerization without
affecting cell proliferation. Thus, our data suggest that p38
MAPK activation by VEGF plays a critical role in HIMEC
migration by regulating actin polymerization dynamics
and organization. Interestingly, another study by Tanaka
and coworkers has demonstrated the importance of
SAPK/p38 MAPK activation as a modulator of endothelial
cell migration in response to bFGF [35].
Treatment of HIMEC with neutralizing VEGFR2 antibody
abolished the cell migration, which was consistent with
the observation that VEGFR2 is a positive regulator of ang-
iogenesis [33]. However, the biochemical events that cou-
ple VEGFR2 to p38 MAPK activation and cell migration
Electrophoretic mobility shift assay of NFATp, NFκB and AP-1 in VEGF and TNF-α/LPS stimulated HIMEC Figure 12
Electrophoretic mobility shift assay of NFATp, NFκB and AP-1 in VEGF and TNF-α/LPS stimulated HIMEC. Nuclear extracts 
from VEGF (50 ng/ml) or TNF-α/LPS stimulated HIMEC with or without CsA (0.1 µM) were subjected to EMSA using probes 
to left panel; the NFAT site of human COX-2 promoter (nucleotides -117 to -91). Middle panel; the NFκB site of the 
human COX-2 promoter (nucleotides -135 to -123). Right panel; the NFAT-AP1 site of the human COX-2 promoter probe 
(nucleotides -82 to -58). CsA inhibited NFAT DNA binding following VEGF activation in HIMEC (A). NFAT was not activated 
by TNF-α/LPS. VEGF did not activate NFκB in HIMEC, which was activated following TNF-α/LPS (B). VEGF activated AP-1, 
which was not inhibited by CsA (C). These data demonstrate the selective inhibitory effect of CsA on NFAT acativation fol-
lowing VEGF stimulation in HIMEC.
VEGF - +       +         - - +        - - +        +
CsA - - +         - - - - - - +
TNF-α/LPS - - - +             - - +            - - -
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are still unknown. Studies have shown that VEGFR1 is
involved in the down-regulation of the VEGFR2 which is
required for angiogenesis [33]. Petrova et al. [36] demon-
strated that VEGFR1 has a higher affinity than VEGFR2 for
VEGF and can titrate VEGF by competing with VEGFR2, so
at low concentration of VEGF, this will establish a thresh-
old for the onset of angiogenesis and allows a down regu-
lation of signal later in the process [33].
VEGF stimulation of endothelial cells results in dephos-
phorylation and translocation of NFATp from the cyto-
plasm to the nucleus in a time dependent fashion. The
calcineurin inhibitor CsA blocked the translocation of
NFATp. It has been shown that in T lymphocytes and
fibroblasts, elevations of intracellular calcium levels result
in calcineurin activation and subsequent activation and
nuclear localization of NFAT proteins [37,38]. These data
suggest that VEGF activation of the calcineurin pathway in
HIMEC leads to the translocation of NFATp to the
nucleus, where it is phosphorylated and then exported to
the cytoplasm. Therefore, it appears that NFATp activation
in HIMECs is regulated by similar mechanisms like those
operating in T cells or fibroblasts.
Effect of VEGF on NFAT, p65 subunit of NFκB, c-fos and c-Jun in HIMEC Figure 13
Effect of VEGF on NFAT, p65 subunit of NFκB, c-fos and c-Jun in HIMEC. Immunofluorescence staining was used to visualize 
nuclear translocation following VEGF induced activation of NFAT, and the p65 subunit of NFκB and AP-1 component (c-fos 
and c-Jun) of HIMEC. In unstimulated HIMEC, NFATp was detected in cytoplasm, and following VEGF activation was translo-
cated to the nucleus, whereas TNF-α/LPS activation of HIMEC did not result in nuclear NFAT translocation. CsA pre-treat-
ment resulted in abrogation of the NFATp nuclear translocation following VEGF stimulation.
TNF-α /LPS
VEGF + CsA
.
.
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NFAT proteins are the major targets of the calcineurin
inhibitors CsA and FK506, and NFAT activation has been
shown to affect the activation of other transcription
factors which may in part explain the potent effect of CsA
and FK506 as immunosuppressive agents [39,40]. CsA
has been shown to play a role in the expression of
cytokines produced by endothelial cells including IL-1, IL-
6, and IL-8 in different cell types [41,42], thus NFAT may
be potentially involved in the transcriptional regulation of
these cytokine genes in endothelial cells. Our data corrob-
orate previous studies demonstrating that NFAT
activation is a key component of the angiogenic response
induced by VEGF in endothelial cells [22], and
modulation of this pathway may represent an adverse
effect of calcineurin inhibition during transplant
immunosuppression. Indeed, an increasing body of
evidence suggests that the pharmacologic strategies which
effectively inhibit acute rejection, may in fact be playing a
central role in the etiogenesis of vascular dysfunction
which is central to the pathology of chronic rejection, and
is emerging as an important cause of morbidity and mor-
tality in solid organ transplant patients in the years fol-
lowing successful engraftment.
The cyclooxygenase enzymes COX-1 and COX-2 have
been shown to play an important role in the regulation of
angiogensis [43]. These enzymes catalyze the conversion
of arachidonic acid to PGH2, the first step in the
VEGF did not lead to translocation of the NFκB-subunit p65, whereas TNF-α/LPS activation of HIMEC resulted in p65 subunit  translocation from cytosol to the nucleus in a CsA-insensitive manner Figure 14
VEGF did not lead to translocation of the NFκB-subunit p65, whereas TNF-α/LPS activation of HIMEC resulted in p65 subunit 
translocation from cytosol to the nucleus in a CsA-insensitive manner.
Unstim
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biosynthesis of the PGs thromboxane and prostacyclin
[44]. In endothelial cells COX-1 is constitutively
expressed, whereas COX-2 is inducible in response to var-
ious activators such as mitogens, hormones and inflam-
matory cytokines [45]. The human COX-2 promoter
contains binding sites for cAMP response element (CRE),
NF-IL6 (C/EBP), and NFκB [46]. An essential role for
NFAT in the induction of COX-2 gene by VEGF in HUVEC
has been reported [22]. However, these investigators did
not evaluate the activation of alternate signaling mecha-
nisms which undergo activation in response to VEGF,
specifically the MAPK family members. Our present study
confirms that COX-2 and NFAT played an important role
in microvascular endothelial angiogenesis induced by
VEGF, but in addition demonstrated a differential
contribution of p44/42 MAPK and p38 MAPK in various
cellular physiologic steps which comprise angiogenesis.
VEGF activation of MAPKs (ERKs, JNKs/SAPKs, and p38
MAPK) signal transduction pathways in endothelial cells
[47,48] are consistent with the VEGF activation of AP-1
that we show here. The MAPKs regulate the AP-1 family
members at the transcriptional and posttranscriptional
levels [49,50]. We have shown the induction of AP-1 by
the AP-1 DNA-binding activity and the translocation of c-
Fos and c-jun from cytoplasm to the nucleus upon VEGF
activation of HIMEC. AP-1 DNA binding was not inhib-
ited by CsA. Given the major role of VEGF in physiologi-
cal and pathological angiogenesis, the identification of
NFAT and AP-1 as transcription factors that couple VEGF
VEGF stimulation of HIMEC also resulted in nuclear translocation of c-fos and c-Jun independent of CsA effect Figure 15
VEGF stimulation of HIMEC also resulted in nuclear translocation of c-fos and c-Jun independent of CsA effect.
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signaling to the transcriptional gene response may help to
localize therapeutic targets to antagonize or modulate the
angiogenic process and to further delineate the upstream
signaling pathways and the specific gene expression pro-
gram triggered by VEGF in endothelial cells.
Perhaps the most important finding in our paper, is the
demonstration of the differential effect of CsA on distinct
signaling pathways which play integral roles in the
complex biologic process of angiogenesis. CsA is known
to exert specific effects on the intracellular signaling cas-
cades, as previously published data from our laboratory
demonstrated that CsA inhibits p38 MAPK activation in
response to TNF-α+ LPS activation in HIMECs [33]. We
evaluated a series of key steps in VEGF induced angiogen-
esis, and found that various members of the MAPK family,
NFAT, AP-1 and COX-2 played primary roles in different
stages of the cell physiology. p38 MAPK played an early
role in stress fiber assembly, and also played a key role in
endothelial cell migration. Monolayer expansion and pro-
liferation of endothelial cells was dependent on p44/42
MAPK and COX-2. Maturation of microvascular endothe-
lial cells in the context of in vitro tube formation was
dependent on p44/42 MAPK, COX-2, NFAT but not p38
MAPK. Our data also demonstrated that NFκB did not
play a role in the VEGF induced angiogenic response, nor
did c-Fos or c-Jun, the components of AP-1. Integrating
the specific effect of CsA on these various stages of angio-
genesis has not been previously described. A major
challenge in defining the regulation of intracellular
cellular activation remains the process of characterizing
the simultaneous activation and interaction of signaling
cascades and networks. Our data demonstrates that MAPK
signaling cascades will be involved in multiple steps in
angiogenesis, playing distinct roles sequentially in the
process. Finally, we have also demonstrated that the sign-
aling responses in HIMEC were dependent on VEGF con-
centration, as higher amounts of this growth factor
resulted in a paradoxical decrease in activation, a phe-
nomenon previously described for the angiogenic chem-
okines [51,14,29].
Our study demonstrates that different signaling pathways
will play dominant roles in individual steps which are
Effect of VEGF on COX-1 and COX-2 mRNA and protein expression in HIMEC Figure 16
Effect of VEGF on COX-1 and COX-2 mRNA and protein expression in HIMEC. Detection of COX-1 and COX-2 mRNA in 
HIMEC by semi-quantitative reverse transcriptase-PCR using specific primers. HIMEC constitutively express mRNA for COX-
1 but not COX-2. Stimulation (3 h) of HIMEC with VEGF (50 ng/ml) led to marked up-regulation of COX-2 gene expression, 
whereas COX-1 was unaffected. CsA, NS398 and PD098059 pre-treatment of HIMEC inhibited COX-2 mRNA expression fol-
lowing VEGF. β-actin, was used as loading control. Representative figure for HIMEC isolates from five different patients.
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involved in a complex biologic process, such as
angiogenesis. The use of complementary in vitro assays for
the assessment of angiogenesis allowed us to characterize
the signaling pathways which were interacting during
VEGF activation. If only one assay had been emphasized,
the overall interplay of signaling cascade activation would
not have been appreciated. At the present time, there is
intense interest in defining the ability of signaling cas-
cades to interact in a coordinated fashion, and likewise, an
attempt to characterize the effect of pharmacologic agents
on cellular activation.
There are important clinical ramifications which can be
envisioned related to the observations in our study.
Pharmacologic approaches using CsA and COX-2
inhibition may exert potent effects on blood vessels,
which are underappreciated at the present time. The
importance of angiogenesis in neoplastic disease and
wound healing are two immediate areas where these phar-
macologic agents may exert beneficial, or potentially del-
eterious effects. Studies focusing on organ specific
microvascular populations may help in determining new
clinical indications for the use of pharmacologic agents
targeting blood vessels.
Conclusion
In summary, CsA exerts potent effects on human microv-
ascular endothelial cells, inhibiting all of the stages of in
vitro  angiogenesis which were evaluated. More impor-
tantly, the effect of CsA was exerted through differential
inhibitory effects on an interplay of signaling cascades,
which contributed to distinct components of
angiogenesis, including stress fiber assembly, migration,
endothelial monolayer expansion and proliferation, and
tube formation. Our data suggests that CsA exerts potent
effects on non-immune vascular cell populations which
may contribute to microvascular dysfunction and the vas-
culopathy which characterizes chronic rejection following
solid organ transplantation. Our findings might help
explain the limited clinical success of human small intes-
tinal transplantation, as the calcineurin inhibitors
required for post-transplant immunosuppression
adversely affect angiogenic and vascular homeostatic
mechanisms in intestinal microvascular endothelial cells.
Finally, defining the effect of the calcineurin inhibitors on
human microvascular endothelial cells may ultimately
open the route for novel anti-angiogenic strategies using
these agents as inhibitors of vessel proliferation for
therapeutic benefit, potentially as adjunctive treatments
of adenocarcinoma.
Material and Methods
Antibodies and reagents
VEGF and anti-human VEGF antibodies (VEGFR1 and
VEGFR2) were from R&D Systems (Minneapolis, MN).
Cyclosporine A (CsA) was from Alexis (San Diego, CA).
Rapamycin, FK506 and the MAPK inhibitors (PD098059,
SB203580) were obtained from Calbiochem (La Jolla,
CA). The selective COX-2 inhibitor NS398 was from
Cayman Chemical Co. (Ann Arbor, MI). Antibodies
against the MAPK superfamily members (p44/42 MAPK,
p38 MAPK, and c-jun NH2-terminal MAPK (SAPK)) were
from New England Biolabs (Beverly, MA). Antibodies to
NFAT, p65 subunit of NF-κB and COX-1/-2 were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA).
Fluorescein-conjugated phalloidin was from Molecular
Probes, Inc. (Eugene, OR). Fluorescein-conjugated
streptavidin was from Pierce (Rockford, IL). Endothelial
Cell Growth Supplement (ECGS) was from Upstate Bio-
tech Inc. (Lake Placid, NY). MCDB-131 medium, porcine
heparin, PSF (penicillin/streptomycin/fungizone), and
soybean trypsin inhibitor were from Sigma (St. Louis,
MO). Fetal bovine serum (FBS) was from Bio Whittaker
(Walkersville, MD). Collagenase type II was from Wor-
thington Biochemical Corporation (Lakewood, NJ), and
bovine serum albumin (BSA, Fraction V) was obtained
from Fisher Scientific (Fair Lawn, NJ). Human plasma
fibronectin was from Chemicon International (Temecula,
CA). Oligonucleotide and primers were from Operon
(Alameda, CA).
VEGF enhances COX-2 protein expression in HIMEC Figure 17
VEGF enhances COX-2 protein expression in HIMEC. West-
ern blot analysis of HIMEC stimulated by various cytokines 
and chemokines revealed that VEGF and TNF-α/LPS activa-
tion resulted in equally enhanced COX-2 protein expression. 
HIMEC were stimulated with TNF-α/LPS, IL-1β, IL-8 and IL-
1β/IL-8 for 3 – 12 h (Data shown is 3 h activation time 
period, which was maximal).
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Primary culture of human intestinal microvascular 
endothelial cells (HIMEC)
Macroscopically normal small intestinal specimens for
HIMEC isolation were obtained from patients undergoing
scheduled bowel resection. The use of human tissues was
approved by the Institutional Review Board of the Medical
College of Wisconsin. HIMEC were isolated from surgical
specimens and maintained as described earlier [28].
HIMEC cultures were recognized by microscopical fea-
tures and modified lipoprotein uptake (Dil-ac-LDL,
Biomedical Technology, Inc., Stoughton, MA) and expres-
sion of Factor VIII-associated antigen. All experiments
were carried out using primary endothelial cell cultures
between passages 8–12.
Endothelial cell chemotaxis assay
Chemotaxis assay was carried out as described earlier [29].
Briefly, using polycarbonate filters (8 µm pore size, Bec-
ton Dickinson Labware, Franklin Lakes, NJ) 5 × 105 cells
were added to the upper chamber, and chemotaxis buffer
(1000 µl) containing VEGF (1–50 ng/ml) was filled into
the lower compartment of the 12-well plates. After 3 hr of
incubation at 37°C, cell culture inserts were removed,
wiped and stained with DiffQuik (Baxter Scientific,
McGraw, IL). Migrated HIMEC adherent to the lower side
of the membrane were counted (ten random high-power-
fields (HPF; 40×) per condition in a blinded fashion). In
inhibition studies, resuspended cells were incubated with
neutralizing anti-VEGFR2 antibody, isotype control anti-
body, CsA (0.1 µM), FK506 (50 nM), Rapamycin (20
nM), SB203580 (5 µM), PD098059 (10 µM) or the
selective COX-2 inhibitor, NS398 (10 µM), for 30 min at
37°C. Cell viability was >95% as assessed by trypan blue
exclusion. Each condition was assessed in triplicate.
Cell proliferation assay
3 × 104 HIMEC per well were seeded onto fibronectin-
coated 24-well plates using growth medium without
ECGS as described earlier [29]. After pre-treatment with
the indicated inhibitors (CsA 0.1 µM, PD098059 10 µM,
Time course of enhanced COX-2 protein expression by VEGF in HIMEC Figure 18
Time course of enhanced COX-2 protein expression by VEGF in HIMEC. VEGF (50 ng/ml) resulted in a maximal increase of 
COX-2 protein at 3 hr which declined after 24 hr as detected by western blotting. There were no changes in COX-1 protein 
expression in VEGF stimulated HIMEC. Pretreatment of HIMEC with 0.1 µM CsA diminished COX-2 protein expression fol-
lowing VEGF. Both NS398 and PD098059 were strong inhibitors of COX-2 protein expression in VEGF stimulated HIMEC 
(not shown).
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SB230580 5 µM, NS398 10 µM) for 30 min at 37°C, cells
were stimulated with VEGF (50 ng/mL) for 24, 48, and 72
hr, or left untreated. Following complete detachment,
cells were re-suspended and counted in a Coulter Counter
(Coulter, Brea, CA). In parallel experiments, cell viability
was assessed by trypan blue exclusion and was greater
than 95%. Each condition was assessed in triplicate.
Cellular DNA synthesis was assessed by 3H-thymidine
uptake in HIMEC as described earlier [29]. HIMEC were
pulsed with 3H-thymidine (1 µCi/ml; Amersham,
Arlington Heights, IL), washed twice on ice with 5% (v/v)
trichloroacetic acid prior to fixation. DNA was then
released from precipitated material by alkaline lysis in 0.5
N NaOH, and supernatants were quantified in a beta-
counter. Each condition was assessed in triplicate.
Microscopic wounding assay
To assess HIMEC migration in response to angiogenic
stimuli, a microscopic wounding assay was performed as
described earlier [52]. In brief, a HIMEC confluent mon-
olayer was scraped along a straight line, and the
remaining monolayer was then incubated with growth
medium (without ECGS), and cells were pretreated for 30
min at 37°C with or without CsA (0.1 µM), SB203580 (5
µM) or PD098059 (10 µM). Then, cells were stimulated
by addition of VEGF (10 ng/ml) or left untreated. The
migration of HIMEC across the demarcation line was
monitored using an inverted microscope. At each time
point (24, 48, and 72 hr), 10 random fields using an
ocular grid were counted in a blinded fashion. Data were
expressed as cells/mm2, and each condition was assessed
in triplicate.
Matrigel™ in vitro-tube formation assay
Endothelial tube formation was assessed using Matrigel™,
a solubilized extracellular basement membrane matrix
extracted from the Engelbreth-Holm-Swarm mouse
sarcoma, as described previously [53]. HIMEC resus-
pended in complete growth medium which were seeded
at a density of 5 × 104 cells per well. Where indicated, the
growth medium was supplemented with CsA (0.1 µM),
PD098059 (10 µM), SB203580 (5 µM) and NS398 (10
µM). Control wells contained no inhibitors. Endothelial
tube formation on Matrigel™ after 16 hr was assessed by
inverted phase contrast microscopy and photographed
with an inverted tissue culture microscope. Five high
power fields per condition were examined and experi-
ments were repeated in two independent HIMEC cultures.
Cellular fractionation and western blot analysis
Confluent HIMEC monolayers in 35-mm culture dishes
(one dish per condition) were pre-treated with various
inhibitors for 30 min or left untreated before VEGF activa-
tion (50 ng/ml) for different time periods (1, 5,10, 15, 20,
30, 60, and 120 min) as described previously [54]. The
homogenates were centrifuged and supernatants
(cytosolic fraction) were removed and protein
concentrations were determined using a Bradford Assay
(Bio-Rad, Hercules, CA). Equal amounts of protein were
separated by SDS-PAGE and transferred to nitrocellulose
membranes [30]. The membranes were blocked for 3 hr at
room temperature in 3% (w/v) BSA, 3% (w/v) nonfat dry
milk in Tris-buffered saline (50 mM Tris-HCl, 150 mM
NaCl, pH 7.4) containing 0.1% (v/v) Tween 20(TBS-T),
then were incubated with specific primary antibodies to
NFATp, COX-2, phosphorylated and non-phosphorylated
MAPK (ERK1/2, p38 MAPK and JNK) at 4°C overnight as
specified. Detection was by secondary antibody coupled
to horseradish peroxidase (HRP) and ECL™ (Amersham
Pharmacia Biotech; Arlington Heights, IL).
Electrophoretic mobility shift assay (EMSA)
Nuclear protein extraction was performed as described
previously [30]. In brief, HIMEC monolayers were lysed
in hypotonic lysis buffer and cell nuclei were collected
and frozen immediately in liquid nitrogen until further
usage. Protein concentrations were determined using a
Bradford assay (Bio-Rad, Hercules, CA). The samples were
then incubated on ice with 32P-labeled double stranded
oligonucleotide for 30 min and DNA-protein complexes
were separated by SDS-PAGE. Dried gels were exposed to
X-ray film to detect DNA binding of NFAT, NF-κB and AP-
1. The synthetic oligonucleotides [22] used as probes in
electrophoretic mobility shift assays (EMSAs) were as fol-
lows: NFAT; 5'-tcgaCAAGGGGAGAGGAGGGAAAAATTT-
GTGGC-3' (nucleotides -117 to -91 containing the NFAT
site of the human COX-2 promoter); NF-κB; 5'-gatcAGT-
GGGGACTACCCCCT-3' (nucleotides -277 to-211 con-
taining the NF-κB site of the human COX-2 promoter)
and for AP-1; 5'-tcgaCAAAAGGCGGAAAGAAACAGT-
CATTTC-3' (nucleotides -82 to -58 containing the NFAT-
AP1 site of the human Cox-2 promoter).
Immunofluorescence staining
F-Actin polymerization was assessed in subconfluent
HIMEC seeded on fibronectin-coated glass chamber slides
(LabTek; Nalge Nunc, Naperville, IL) as described previ-
ously [29]. Cells were cultured in MCDB-131 without FBS
for 12 hr and pretreated for 30 min at 37°C with or with-
out CsA (0.1 µM), SB203580 (5 µM) or PD098059 (10
µM). HIMEC were then stimulated with 10–50 ng/ml
recombinant human VEGF (1–15 min), and fixed with
3.7% (v/v) formaldehyde in PBS for 20 min at room tem-
perature. Cells were washed and permeabilized with Tri-
ton X-100 (0.1% (v/v) in PBS) for 10 min, blocked with
2.5% (w/v) BSA/PBS, and stained with fluorescein-phal-
loidin (Molecular Probes, Eugene, OR). After washing,
slides were air dried and mounted with Fluoromount-G
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examined with a fluorescence microscope (Olympus BX-
40) using a fixed shutter speed to allow for comparison of
fluorescence intensity. In some experiments, stress fiber
assembly was blocked by pre-incubation of cells with 10
µg/ml VEGFR2 antibody, (30 min at 37°C).
For immunofluoresence staining to demonstrate translo-
cation of NFAT, p65 (NF-κB subunit), c-Jun and c-Fos
(AP-1 subunit), cells were grown as above, left untreated
or pre-treated with CsA (0.1 µM) before VEGF (50 ng/ml)
or TNF-α/LPS (TNF-α 100 units/ml, LPS 1 µg/ml) for 30
min. Cells were then fixed with 3% (w/v) paraformalde-
hyde in phosphate-buffered saline (PBS) for 15 min at
room temperature and washed three times (5 min each)
with washing buffer (PBS, 0.01% (v/v) Nonidet P-40 [NP-
40]). After blocking for 30 min as above, the cover slips
were incubated with the anti-NFATp, p65, c-Jun,
phospho-c-Jun and c-Fos antibodies for 60 min at room
temperature. Unbound antibody was removed by rinsing
three times with washing buffer and the cover slips were
incubated for 30 min with a fluorescein-conjugated sec-
ondary antibody (Santa Cruz), washed three times,
mounted and visualized as above.
RNA preparation and semi-quantitative RT-PCR
For determination of COX-1 and COX-2 mRNA expres-
sion, confluent HIMEC cultures were serum starved for 12
hr and stimulated with VEGF (50 ng/ml) with or without
inhibitors for 3, 6 and 12 hr. Total RNA was extracted
using TRIzol (Life Technologies, Rockville, MD) and
treated with Deoxyribonuclease I, Amplification Grade
(Life Technologies) according to the manufacturer's
instruction. The complementary DNA (cDNA) was gener-
ated from 1 µg of total RNA with oligo (dT) primer using
Superscript First-Strand Synthesis System for RT-PCR (Life
Technologies) according to the protocol and in a total
volume of 80 µl. Four µl of cDNA solution were used for
polymerase chain reaction (PCR) in a total volume of 40
µl containing 1.5 mM MgCl2, 0.2 mM dNTP mix, 0.5 µM
of sense and anti-sense primers, respectively, and 1 IU of
Taq polymerase (Life Technologies). PCR amplifications
were performed 30 cycles for COX-1 (94°C for 1 min,
56°C for 1 min, 72°C for 1 min), 35 cycles for COX-2
(94°C for 1 min, 54°C for 1 min, 72°C for 1 min) and 25
cycles for β-actin (94°C for 1 min, 60°C for 1 min, 72°C
for 1 min), using COX-1, COX-2 and β-actin specific
primers (below) and followed by final extension for 7
min at 72°C. Twenty µl of PCR product were visualized
on 1.2% agarose gels stained with ethidium bromide.
RNA solution without reverse transcription was used as
negative control (no RT), and β-actin served as an internal
control. Primer sequences used are shown in table 1.
Analysis of data
Statistical Analysis was performed using Statview 4.5 and
superANOVA software for the Macintosh. When single
comparisons were made, t-tests were used, applying
paired or unpaired analysis as appropriate. When
multiple comparisons between groups were performed
one way or two-way analysis of variance was used as
appropriate followed by the Student-Newman Keuls test.
P ≤ 0.05 was considered significant.
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Table 1: Human COX-1, COX-2 and Bata-actin primers
COX-1 forward (5'-TGCCCAGCTCCTGGCCCGCCGCT-3')
COX-1 reverse (5'-TTCAAATGAGATTGTGGGAAAATTGTC-3')
COX-2 forward (5'-TCAAATGAGATTGTGGGAAAATTG-3')
COX-2 reverse 5'-TCTAGTAGAGACGGACTCATAGAA-3')
β-actin forward (5'-CCAGAGCAAGAGAGGCATCC-3')
β-actin reverse (5'-CTGTGGTGGTGAAGCTGTAG-3')Cell Communication and Signaling 2004, 2 http://www.biosignaling.com/content/2/1/3
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